J&J to im­pose new lim­its on 340B ac­cess af­ter in­dus­try court win

One phar­ma gi­ant is im­ple­ment­ing some ma­jor re­stric­tions on ac­cess to 340B drugs, which go in­to ef­fect next month.

John­son & John­son an­nounced last week that it is up­dat­ing its 340B pol­i­cy ef­fec­tive Mar. 7, which will in­clude re­strict­ing non-grantee cov­ered en­ti­ties to on­ly one con­tract phar­ma­cy to dis­pense out­pa­tient drugs cov­ered un­der 340B. The pol­i­cy, which in­cludes whether the ap­proved health cen­ters and hos­pi­tals have an in-house phar­ma­cy or not, set the con­di­tions that they must pro­vide lim­it­ed claims da­ta, and that the one con­tract phar­ma­cy must be with­in 40 miles of the ap­proved health care en­ti­ty’s par­ent site.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN